New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

2 SOURCES CONFIRMED · FIRST SEEN 2026-10-12 20:05 UTC

EXHIBIT · mmx.prnewswire.com

KINDNews

DIRECTION▲ Bullish

SOURCES2

ENTITIES2

STORY SIZE2 RECORDS

FIRST SEEN2026-10-12 20:05 UTC

LAST UPDATE2026-10-12 20:05 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Consistent fistula remission across hard-to-treat subgroups supports expanded use in Crohn's disease.

Fistula data broadens Crohn's positioning

CATALYST TO WATCH

Regulatory filings for expanded indication

MAIN RISK

Small subgroup sizes limit statistical weight

FULL DISPATCH

New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

UPDATED 2 TIMES · FIRST 2026-10-12 20:05 UTC · LAST 2026-10-12 20:05 UTC

2026-10-12 20:05 UTCNewsNew TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroupsCURRENT RECORD

2026-10-12 20:05 UTCNewsTREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease

03 WHO'S INVOLVED